Why is aortic sclerosis associated with adverse clinical outcomes?

Journal of the American College of Cardiology

Volumn 43, Issue 2, 2004, Pages 176-178

  Otto, Catherine M ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; ANTILIPEMIC AGENT; C REACTIVE PROTEIN; CALCIUM; DIPEPTIDYL CARBOXYPEPTIDASE; FIBRINOGEN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MATRIX METALLOPROTEINASE; TENASCIN;

ANGINA PECTORIS; AORTA ATHEROSCLEROSIS; AORTA STENOSIS; AORTA VALVE; AORTA VALVE DISEASE; AORTA VALVE REPLACEMENT; APOPTOSIS; ATHEROSCLEROSIS; CALCIFICATION; CALCINOSIS; CALCIUM METABOLISM; CELL PROLIFERATION; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY RISK; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; EDITORIAL; ENDOTHELIUM LESION; GENETIC POLYMORPHISM; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEMODYNAMICS; HUMAN; INFLAMMATION; INFLAMMATORY INFILTRATE; LIPID OXIDATION; MITRAL VALVE DISEASE; NONHUMAN; PATHOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SCLEROSIS; SHEAR STRESS; STROKE; TENSILE STRENGTH; TREATMENT OUTCOME; VALVULAR HEART DISEASE; VASCULAR ENDOTHELIUM;

EID: 1042264341     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2003.10.027     Document Type: Editorial

References (33)

1. Stewart B.F., Siscovick D., Lind B.K., et al. Clinical factors associated with calcific aortic valve disease. J Am Coll Cardiol. 29:1997;630-634.
2. Lindroos M., Kupari M., Heikkila J., et al. Prevalence of aortic valve abnormalities in the elderly an echocardiographic study of a random population sample . J Am Coll Cardiol. 21:1993;1220-1225.
3. Agmon Y., Khandheria B.K., Meissner I., et al. Aortic valve sclerosis and aortic atherosclerosis different manifestations of the same disease? Insights from a population-based study . J Am Coll Cardiol. 38:2001;827-834.
4. Boon A., Cheriex E., Lodder J., et al. Cardiac valve calcification characteristics of patients with calcification of the mitral annulus or aortic valve . Heart. 78:1997;472-474.
5. Lindroos M., Kupari M., Valvanne J., et al. Factors associated with calcific aortic valve degeneration in the elderly. Eur Heart J. 15:1994;865-870.
6. Otto C.M., Kuusisto J., Reichenbach D.D., et al. Characterization of the early lesion of 'degenerative' valvular aortic stenosis histologic and immunohistochemical studies . Circulation. 90:1994;844-853.
7. O'Brien K.D., Reichenbach D.D., Marcovina S.M., Kuusisto J., Alpers C.E., Otto C.M. Apolipoproteins B, (a) and E accumulate in the morphologically early lesion of "degenerative" valvular aortic stenosis. Arterioscler Thromb Vasc Biol. 16:1996;523-532.
8. Olsson M., Thyberg J., Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol. 19:1999;1218-1222.
9. Mohler E.R. III, Chawla M.K., Chang A.W., et al. Identification and characterization of calcifying valve cells from human and canine aortic valves. J Heart Valve Dis. 8:1999;254-260.
10. Rajamannan N.M., Subramaniam M., Rickard D., et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation. 107:2003;2181-2184.
11. O'Brien K.D., Shavelle D.M., Caulfield M.T., et al. Association of angiotensin-converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation. 106:2002;2224-2230.
12. Satta J., Melkko J., Pollanen R., et al. Progression of human aortic valve stenosis is associated with tenascin-C expression. J Am Coll Cardiol. 39:2002;96-101.
13. Jian B., Jones P.L., Li Q., Mohler E.R. III, Schoen F.J., Levy R.J. Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis. Am J Pathol. 159:2001;321-327.
14. Edep M.E., Shirani J., Wolf P., Brown D.L. Matrix metalloproteinase expression in nonrheumatic aortic stenosis. Cardiovasc Pathol. 9:2000;281-286.
15. Rajamannan N.M., Subramaniam M., Springett M., et al. Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve. Circulation. 105:2002;2660-2665.
16. Drolet M.C., Arsenault M., Couet J. Experimental aortic valve stenosis in rabbits. J Am Coll Cardiol. 41:2003;1211-1217.
17. Otto CM. Aortic stenosis. In: Otto CM, editor. Valvular Heart Disease. 2nd ed. Philadelphia, PA: W.B. Saunders, 2004;197-246.
18. Olsen MH, Wachtell K, Bella JN, Palmieri V, Gerdts E, Nieminen MS, et al. Does aortic valve sclerosis predict cardiovascular events independently of albuminuria in hypertension? A LIFE study (abstr). J Am Coll Cardiol 2003;41 Suppl A:510A.
19. Fox C.S., Vasan R.S., Parise H., et al. Mitral annular calcification predicts cardiovascular morbidity and mortality the Framingham Heart Study . Circulation. 107:2003;1492-1496.
20. Adler Y., Vaturi M., Fink N., et al. Association between mitral annulus calcification and aortic atheroma a prospective transesophageal echocardiographic study . Atherosclerosis. 152:2000;451-456.
21. Aronow W.S., Koenigsberg M., Kronzon I., et al. Association of mitral anular calcium with new thromboembolic stroke and cardiac events at 39-month follow-up in elderly patients. Am J Cardiol. 65:1990;1511-1512.
22. Cosmi J.E., Kort S., Tunick P.A., et al. The risk of the development of aortic stenosis in patients with "benign" aortic valve thickening. Arch Intern Med. 162:2002;2345-2347.
23. Otto C.M., Burwash I.G., Legget M.E., et al. A prospective study of asymptomatic valvular aortic stenosis clinical, echocardiographic, and exercise predictors of outcome . Circulation. 95:1997;2262-2270.
24. Rosenhek R., Binder T., Porenta G., et al. Predictors of outcome in severe asymptomatic aortic valve stenosis. N Engl J Med. 343:2000;611-617.
25. Chandra HR, Goldstein JA, Choudhary N, et al. Adverse outcome in aortic sclerosis is associated with coronary artery disease and inflammation. J Am Coll Cardiol 2004;43:169-75.
26. Galante A., Pietroiusti A., Vellini M., et al. C-reactive protein is increased in patients with degenerative aortic valvular stenosis. J Am Coll Cardiol. 38:2001;1078-1082.
27. Poggianti E., Venneri L., Chubuchny V., Jambrik Z., Baroncini L.A., Picano E. Aortic valve sclerosis is associated with systemic endothelial dysfunction. J Am Coll Cardiol. 41:2003;136-141.
28. Ortlepp J.R., Hoffmann R., Ohme F., Lauscher J., Bleckmann F., Hanrath P. The vitamin D receptor genotype predisposes to the development of calcific aortic valve stenosis. Heart. 85:2001;635-638.
29. Avakian S.D., Annicchino-Bizzacchi J.M., Grinberg M., et al. Apolipoproteins AI, B, and E polymorphisms in severe aortic valve stenosis. Clin Genet. 60:2001;381-384.
30. Shavelle D.M., Takasu J., Budoff M.J., Mao S., Zhao X.Q., O'Brien K.D. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet. 359:2002;1125-1126.
31. Pohle K., Maffert R., Ropers D., et al. Progression of aortic valve calcification association with coronary atherosclerosis and cardiovascular risk factors . Circulation. 104:2001;1927-1932.
32. Bellamy M.F., Pellikka P.A., Klarich K.W., Tajik A.J., Enriquez-Sarano M. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol. 40:2002;1723-1730.
33. Novaro G.M., Tiong I.Y., Pearce G.L., Lauer M.S., Sprecher D.L., Griffin B.P. Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. Circulation. 104:2001;2205-2209.